Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 601–700 of 1,012
Wang, C., Liao, Y., He, W. A., Zhang, H., Zuo, D., Liu, W., Yang, Z., Qiu, J., Yuan, Y., Li, K., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01904-y · Cited by 55
Chen, D., Su, X., Zhu, L., Hao, J., Han, B., Chen, H., Liang, Q., Hu, C., Yang, H., Liu, L., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-022-03848-z · Cited by 51
Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., et al. (2024) · Future Oncology · doi:10.2217/fon-2022-1249 · Cited by 46
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 57
Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers
Rubinson, D. A., Tanaka, N., Fece de la Cruz, F., Kapner, K. S., Rosenthal, M. H., Norden, B. L., Barnes, H., Ehnstrom, S., Morales-Giron, A. A., Brais, L. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1138 · Cited by 43
Opportunities and challenges provided by crosstalk between signalling pathways in cancer
Prahallad, A., & Bernards, R. (2015) · Oncogene · doi:10.1038/onc.2015.151 · Cited by 56
Self-citationZheng, Y., Thomas‐Schoemann, A., Sakji-Dupré, L., Boudou, P., Dupin, N., Mortier, L., Vidal, M., Goldwasser, F., & Blanchet, B. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.03.017 · Cited by 50
Choosing wisely – Preclinical test models in the era of precision medicine
Klinghammer, K. F., Walther, W., & Hoffmann, J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.009 · Cited by 52
MTOR inhibitor-based combination therapies for pancreatic cancer
Hassan, Z., Schneeweis, C., Wirth, M., Veltkamp, C., Dantes, Z., Feuerecker, B., Ceyhan, G. O., Knauer, S. K., Weichert, W., Schmid, R. M., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.421 · Cited by 55
Herr, R., Halbach, S., Heizmann, M., Busch, H. S., Boerries, M., & Brummer, T. (2018) · Oncogene · doi:10.1038/s41388-017-0063-5 · Cited by 54
y Cajal, S. R., Segura, M. F., & Hümmer, S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00281 · Cited by 53
Yang, S., Huang, Y., & Zhao, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878740 · Cited by 54
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States
Kim, J. W., Abudayyeh, O. O., Yeerna, H., Yeang, C., Stewart, M. L., Jenkins, R. W., Kitajima, S., Konieczkowski, D. J., Medetgul-Ernar, K., Cavazos, T. B., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2017.08.002 · Cited by 54
Bando, H., Yoshino, T., Shinozaki, E., Nishina, T., Yamazaki, K., Yamaguchi, K., Yuki, S., Kajiura, S., Fujii, S., Yamanaka, T., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-405 · Cited by 54
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 61
Ashraf, S. Q., Nicholls, A. M., Wilding, J. L., Ntouroupi, T. G., Mortensen, N. J., & Bodmer, W. F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218750110 · Cited by 47
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
Rothenberg, S. M., Concannon, K., Cullen, S. J., Boulay, G., Turke, A. B., Faber, A. C., Lockerman, E. L., Rivera, M. N., Engelman, J. A., Maheswaran, S., et al. (2015) · eLife · doi:10.7554/elife.06132 · Cited by 50
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer
Graham, D. M., Coyle, V. M., Kennedy, R. D., & Wilson, R. H. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0312-y · Cited by 60
Adaptive resistance to targeted therapies in cancer.
Rosell, R., Karachaliou, N., Morales-Espinosa, D., Costa, C., Molina‐Vila, M. Á., Sansano, I., Gascó, A., Viteri, S., Massutí, B., Wei, J., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.08 · Cited by 57
Liu, Z., Zhang, Y., Dang, Q., Wu, K., Jiao, D., Li, Z., Sun, Z., & Han, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632430 · Cited by 54
Disrupted molecular glue complex drives RAS inhibitor resistance
Sang, B., Ye, L. F., Fu, Z., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Hu, F., Washington, A., Rodriguez, D. J., Vides, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.031 · Cited by 53
Comparative Aspects of BRAF Mutations in Canine Cancers
Mochizuki, H., & Breen, M. (2015) · Veterinary Sciences · doi:10.3390/vetsci2030231 · Cited by 53
Liu, Q., Bai, X. F., Li, H., Zhang, Y., Zhao, Y., Zhang, X., & Ye, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28154 · Cited by 49
Targeted therapy in rare cancers—adopting the orphans
Munoz, J. L., & Kurzrock, R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.160 · Cited by 53
Venkatesan, S., Lamfers, M. L. M., Dirven, C. M. F., & Leenstra, S. (2016) · CNS Oncology · doi:10.2217/cns-2015-0005 · Cited by 53
Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
Ma, P., Fu, Y., Chen, M., Jing, Y., Wu, J., Li, K., Shen, Y. H., Gao, J., Wang, M., Zhao, X., et al. (2016) · Theranostics · doi:10.7150/thno.14409 · Cited by 53
Bond, C., & Whitehall, V. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/9250757 · Cited by 55
Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020) · Cells · doi:10.3390/cells9122601 · Cited by 52
Chiu, Y., Yang, J., Tsai, F., Chiu, H., Juan, Y., Lo, Y., & Chiang, J. (2022) · Environmental Toxicology · doi:10.1002/tox.23450 · Cited by 49
Yu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
“The benefit of utilizing BRAF inhibitors does not apply to colorectal cancer due to the rapid feedback activation of EGFR [109].”
BackgroundLarge-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Cheraghchi-Bashi-Astaneh, A., Coker, E. A., Bulusu, K. C., Jaaks, P., Crafter, C., Lightfoot, H. W., Milo, M., McCarten, K., Jenkins, D. F., van der Meer, D. J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0388 · Cited by 48
Tripathy, D., Harnden, K. K., Blackwell, K., & Robson, M. E. (2014) · BMC Medicine · doi:10.1186/s12916-014-0140-3 · Cited by 58
Tissue-Agnostic Drug Development
Flaherty, K. T., Le, D. T., & Lemery, S. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_173855 · Cited by 52
Abdel‐Maksoud, M. S., Ammar, U. M., & Oh, C. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.03.062 · Cited by 47
Tan, J., Liu, R., Zhu, G., Umbricht, C. B., & Xing, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004707117 · Cited by 47
Béal, J., Pantolini, L., Noël, V., Barillot, E., & Calzone, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007900 · Cited by 53
Glial Progenitors as Targets for Transformation in Glioma
Ilkhanizadeh, S., Lau, J., Huang, M., Foster, D. J., Wong, R. A., Frantz, A., Wang, S., Weiss, W. A., & Persson, A. I. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00001-9 · Cited by 53
Orlando, E., Aebersold, D. M., Medová, M., & Zimmer, Y. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.12.001 · Cited by 47
Mourragui, S. M. C., Loog, M., Vis, D. J., Moore, K., Manjón, A. G., van de Wiel, M. A., Reinders, M. J. T., & Wessels, L. F. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106682118 · Cited by 57
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Wang, P., Laster, K. V., Jia, X., Dong, Z., & Liu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01903-x · Cited by 47
Gross, A., Niemetz-Rahn, A., Nonnenmacher, A., Tucholski, J., Keilholz, U., & Fusi, A. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0318-9 · Cited by 51
Jürgensmeier, J. M., Eder, J. P., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0753 · Cited by 47
Emerging innovations in clinical trial design
Berry, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.285 · Cited by 46
Huijberts, S. C. F. A., van Geel, R. M. J. M., van Brummelen, E. M. J., Opdam, F. L., Marchetti, S., Steeghs, N., Pulleman, S. M., Thijssen, B., Rosing, H., Monkhorst, K., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04066-4 · Cited by 48
Self-citationPatient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma
Ramzy, G. M., Koessler, T., Ducrey, E., McKee, T., Ris, F., Buchs, N. C., Rubbia‐Brandt, L., Dietrich, P., & Nowak-Sliwinska, P. M. (2020) · Cancers · doi:10.3390/cancers12061423 · Cited by 47
High-throughput, multiparameter analysis of single cells
Haselgrübler, T., Haider, M., Ji, B., Juhász, K., Sonnleitner, A., Balogi, Z., & Hesse, J. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-7485-x · Cited by 46
Critical transition and reversion of tumorigenesis
Shin, D., & Cho, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00969-3 · Cited by 48
Maus, M. K. H., Hanna, D. L., Stephens, C. L., Astrow, S. H., Yang, D., Grimminger, P., Loupakis, F., Hsiang, J., Zeger, G. D., Wakatsuki, T., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.73 · Cited by 48
Drug sensitivity in cancer cell lines is not tissue-specific
Jaeger, S., Duran‐Frigola, M., & Aloy, P. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0312-6 · Cited by 53
Yu, J., Silva, J., & Califano, A. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv556 · Cited by 45
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives
Holch, J. W., Stintzing, S., & Heinemann, V. (2016) · Visceral Medicine · doi:10.1159/000446052 · Cited by 51
Nakamura, Y., Hattori, N., Iida, N., Yamashita, S., Mori, A., Kimura, K., Yoshino, T., & Ushijima, T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.017 · Cited by 45
Yao, Y.-M. M., Donoho, G. P., Iversen, P. W., Zhang, Y., Van Horn, R. D., Forest, A., Novosiadly, R. D., Webster, Y. W., Ebert, P., Bray, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3250 · Cited by 44
Laurenzana, A., Margheri, F., Biagioni, A., Chillà, A., Pimpinelli, N., Ruzzolini, J., Peppicelli, S., Andreucci, E., Calorini, L., Serratì, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.024 · Cited by 45
Llauradó, M., Dawson, A., Hoenisch, J., Kim, H. H., Bamford, S., Salamanca, C. M., DiMattia, G. E., Shepherd, T. G., Cremona, M., Hennessy, B. T., et al. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0725-1 · Cited by 49
Network-based cancer precision medicine: A new emerging paradigm
Tan, A., Huang, H., Zhang, P., & Li, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.015 · Cited by 46
Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment
Russo, M., Sogari, A., & Bardelli, A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1588 · Cited by 52
Self-citationGuo, G., Gong, K., Beckley, N. A., Zhang, Y., Yang, X., Chkheidze, R., Hatanpaa, K. J., Garzón-Muvdi, T., Koduru, P. R. K., Nayab, A., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00962-4 · Cited by 45
Cancer heterogeneity: origins and implications for genetic association studies
Urbach, D., Lupien, M., Karagas, M. R., & Moore, J. H. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.07.001 · Cited by 47
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
Papadakis, A. I., Sun, C., Knijnenburg, T., Xue, Y., Grernrum, W., Hölzel, M., Nijkamp, W., Wessels, L. F. A., Beijersbergen, R. L., Bernards, R., et al. (2015) · Cell Research · doi:10.1038/cr.2015.16 · Cited by 46
Self-citationKawakami, H., Huang, S., Pal, K., Dutta, S. K., Mukhopadhyay, D., & Sinicrope, F. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0017 · Cited by 41
Self-citationRole of Biologics in First-Line Treatment of Colorectal Cancer
Mahipal, A., & Grothey, A. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018382 · Cited by 39
Shao, W., Mishina, Y. M., Feng, Y., Caponigro, G., Cooke, V. G., Rivera, S., Wang, Y., Shen, F., Korn, J. M., Mathews Griner, L. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2033 · Cited by 44
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro, C., Matos, I. G., Martín-Liberal, J., de Olza, M. O., & Garralda, E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3694 · Cited by 49
Duong, H. Q., Nemazanyy, I., Rambow, F., Tang, S. C., Delaunay, S., Tharun, L., Florin, A., Büttner, R., Vandaele, D., Close, P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3149 · Cited by 45
A systematic analysis of signaling reactivation and drug resistance
Kholodenko, B. Ν., Rauch, N., Kölch, W., & Rukhlenko, O. S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109157 · Cited by 44
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252516 · Cited by 48
Komatsu, N., Fujita, Y., Matsuda, M., & Aoki, K. (2015) · Oncogene · doi:10.1038/onc.2015.16 · Cited by 46
Molecular Testing in Colorectal Cancer
Shi, C., & Washington, K. M. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpi83dinulujni · Cited by 51
New tools for old drugs: Functional genetic screens to optimize current chemotherapy
Gerhards, N. M., & Rottenberg, S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.001 · Cited by 47
BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition
Moujaber, T., Etemadmoghadam, D., Kennedy, C. J., Chiew, Y.-E., Balleine, R. L., Saunders, C. A. B., Wain, G., Gao, B., Hogg, R. J., Srirangan, S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00221 · Cited by 45
Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer
Zaballos, M. A., Acuña-Ruíz, A., Morante, M., Crespo, P., & Santisteban, P. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0098 · Cited by 44
Coppé, J.-P., Mori, M., Pan, B., Yau, C., Wolf, D. M., Ruiz-Saenz, A., Brunen, D., Prahallad, A., Cornelissen-Steijger, P., Kemper, K., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0328-z · Cited by 36
Self-citationRAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
Malapelle, U., Passiglia, F., Cremolini, C., Reale, M. L., Pepe, F., Pisapia, P., Avallone, A., Cortinovis, D. L., Stefano, A. D., Fassan, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.015 · Cited by 44
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)
Tabbò, F., Pisano, C., Mazières, J., Mezquita, L., Nadal, E., Planchard, D., Pradines, A., Santamaría, D., Swalduz, A., Ambrogio, C., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102335 · Cited by 47
Omics and therapy – A basis for precision medicine
Garay, J. P., & Gray, J. W. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.009 · Cited by 54
Yang, Y.-P., Zhu, F., Wang, Q., Ding, Y., Rong-biao, Y., & Zeng, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s186498 · Cited by 50
Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer
Kasi, P. M., Afable, M. G., Herting, C. J., Lukanowski, M., & Jin, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad262 · Cited by 47
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
Rosell, R., Codony‐Servat, J., González, J., Santarpía, M., Jain, A. S., Shivamallu, C., Wang, Y., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Nilsson, J. A., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104228 · Cited by 47
BRAF inhibitors: From the laboratory to clinical trials
Rahman, M., Salajegheh, A., Smith, R. A., & Lam, A. K.-Y. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.008 · Cited by 44
Prioritizing therapeutic targets using patient-derived xenograft models
Lodhia, K. A., Hadley, A. M., Haluska, P., & Scott, C. L. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.002 · Cited by 47
Advances in the Management of Low-Grade Gliomas
Rao, A. A. N., & Packer, R. J. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0398-9 · Cited by 45
Parker, R. S., Clifton-Bligh, R. J., & Molloy, M. P. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0938 · Cited by 47
Connolly, K., Brungs, D., Szeto, E., & Epstein, R. J. (2013) · Current Oncology · doi:10.3747/co.21.1661 · Cited by 42
EGFR and MEK Blockade in Triple Negative Breast Cancer Cells
Maiello, M. R., D’Alessio, A., Bevilacqua, S., Gallo, M., Normanno, N., & Luca, A. D. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25220 · Cited by 44
Maleka, A., Åström, G., Byström, P., & Ullenhag, G. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2657-7 · Cited by 44
Johnson, B., Jin, Z., Truty, M. J., Smoot, R. L., Nagorney, D. M., Kendrick, M. L., Kipp, B. R., & Grothey, A. F. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0230 · Cited by 47
Hight, S. K., Mootz, A. A., Kollipara, R. K., McMillan, E. A., Yenerall, P. M., Yoichi, O., Li, L.-S., Avila, K., Peyton, M., Rodriguez‐Canales, J., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.04.005 · Cited by 67
Shrestha, R., Llauradó, M., Dawson, A., Hoenisch, J., Volik, S. V., Lin, Y., Anderson, S. A., Kim, H. H., Haegert, A. M., Colborne, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2222 · Cited by 45
Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
Rudolph, J., Settleman, J., & Malek, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0260 · Cited by 37
Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma
Schreck, K. C., Morin, A., Zhao, G., Allen, A. N., Flannery, P., Glantz, M., Green, A. L., Jones, C., Jones, K. L., Kilburn, L. B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2660 · Cited by 42
Bozic, I., & Nowak, M. A. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042716-094839 · Cited by 41
A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma
Siraj, A. K., Bu, R., Prabhakaran, S., Bavi, P. P., Beg, S., Hazmi, M. A., Al-Rasheed, M. M., Alobaisi, K., Al‐Dayel, F., AlManea, H. M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-168 · Cited by 45
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia
Cremer, A., Ellegast, J. M., Alexe, G., Frank, E. S., Ross, L. S., Chu, S. H., Pikman, Y., Robichaud, A. L., Goodale, A. B., Häupl, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0209 · Cited by 43
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
Klute, K. A., Rothe, M., Garrett-Mayer, E. S., Mangat, P. K., Nazemzadeh, R., Yost, K. J., Duvivier, H. L., Ahn, E. R., Cannon, T. L., Alese, O. B., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00191 · Cited by 46
Li, B., Ming, H., Qin, S., Zhou, L., Huang, Z., Jin, P., Peng, L., Luo, M., Zhang, T., Wang, K., et al. (2023) · Advanced Science · doi:10.1002/advs.202306535 · Cited by 54
Understanding resistance to targeted cancer drugs through loss of function genetic screens
Berns, K., & Bernards, R. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.002 · Cited by 44
Self-citationSelbo, P. K., Bostad, M., Olsen, C. E., Edwards, V. T., Høgset, A., Weyergang, A., & Berg, K. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00027k · Cited by 41
Molecular targeted therapies in metastatic melanoma
Comfere, N. I., Chakraborty, & Wieland, W. (2013) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s44800 · Cited by 48
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.